Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 61
News
News | 01 December 2023

Biocon Biologics completes Integration of Viatris' Biosimilar business

The full transition of Viatris' biosimilars operations to Biocon Biologics in Europe represents another significant milestone

News
News | 01 December 2023

Cipla partners with TEACH to create career opportunities for hearing-impaired youth

The company also organised sensitization workshops for its employees aimed at increasing awareness of challenges faced by hearing-impaired individuals

News
News | 01 December 2023

New global survey finds widespread misunderstandings about shingles despite its lifetime prevalence

A new GSK survey shows a large number of adults do not understand how shingles may be triggered

News
News | 30 November 2023

CPHI & PMEC India 2023 redefines pharma landscape

South Asia’s largest Trade Fair for pharma brought together over 50,000 visitors from across the globe, more than 1,500 exhibitors showcasing 10,000+ products and representation from over 80 countries

News
News | 30 November 2023

Cadila launches Rs. 200 crore API facility in Dahej

Equipped with most advanced Distributed Control System (DCS) automation technology, the facility has been set up with an investment of Rs. 200 crore

News
News | 29 November 2023

Bayer commits to Veeva Vault CRM and Veeva OpenData globally

Establishes connected software and data foundation for the future with next-generation life sciences CRM and harmonized customer data

News
News | 29 November 2023

Aster to separate its India and GCC businesses to unlock value

Both the India and GCC entities will be operated by separate dedicated management teams

News
News | 28 November 2023

Fortis Healthcare to divest Fortis Malar Hospital, Chennai to MGM Healthcare

The divestment is a part of Fortis' ongoing portfolio rationalization strategy

News
News | 28 November 2023

GSK announces positive results from DREAMM-7 head-to-head phase III trial for Blenrep

Blenrep (belantamab mafodotin) plus BorDex showed statistically significant progression-free survival (PFS) benefit versus daratumumab plus BorDex

News
News | 25 November 2023

Laurus Labs acquires 87.59% stake in Laurus Bio Private

Laurus Labs concluded the acquisition by securing the remaining 8,333 equity shares from the promoter group shareholders

News
News | 25 November 2023

DxVx plans to make a license-in agreement of OVM-200

Final stage in licensing OVM-200 from Oxford Vacmedix in the UK

News
News | 23 November 2023

AstraZeneca Pharma India receives permission to Import formulations of new drug for sale

The receipt of this permission paves way for the launch of Olaparib film coated tablets in India

News
News | 23 November 2023

Merck to acquire Caraway Therapeutics

Acquisition underscores Merck’s ongoing commitment to developing treatments for neurodegenerative diseases

News
News | 23 November 2023

Fosun Pharma USA and Treehill Partners to invest in biopharma space

The newly established business will be looking for high-quality, mid- to late-stage assets, clinically focused on the United States market

News
News | 23 November 2023

Lupin launches Vilfuro-G for COPD Management in India

Lupin Vilfuro-G is the only FDC that uniquely combines Vilanterol, Fluticasone Furoate and Glycopyrronium Bromide

News
News | 23 November 2023

Prevest Denpro launches range of innovative oral hygiene products ‘Oradox’

The Oradox brand introduced a range of revolutionary products designed to elevate the standard of oral care

News
News | 21 November 2023

Mandaviya visits Jan Aushadhi stall at IITF

Jan Ausahdhi exhibited demonstration stall during 42nd India International Trade Fair to spread awareness

News
News | 21 November 2023

Mandaviya visits Ayushman Bhav Health Pavilion at the 42nd IITF 2023

Distributes Ayushman cards to several beneficiaries

News
News | 21 November 2023

AstraZeneca launches health-tech business ‘Evinova’

Evinova will operate as a separate health-tech business within AstraZeneca

News
News | 21 November 2023

Oceanic-AF study stopped early due to lack of efficacy

OCEANIC-AF is one trial which evaluates asundexian versus apixaban in patients with atrial fibrillation at risk for stroke within the overall OCEANIC phase III program

Startup

Digitization